Abstract
Mucosal vaccines based on rice (MucoRice) offer a highly practical and cost-effective strategy for vaccinating large populations against mucosal infections. However, the limitation of low expression and yield of vaccine antigens with high molecular weight remains to be overcome. Here, we introduced RNAi technology to advance the MucoRice system by co-introducing antisense sequences specific for genes encoding endogenous rice storage proteins to minimize storage protein production and allow more space for the accumulation of vaccine antigen in rice seed. When we used RNAi suppression of a combination of major rice endogenous storage proteins, 13 kDa prolamin and glutelin A in a T-DNA vector, we could highly express a vaccine comprising the 45 kDa C-terminal half of the heavy chain of botulinum type A neurotoxin (BoHc), at an average of 100 μg per seed (MucoRice-BoHc). The MucoRice-Hc was water soluble, and was expressed in the cytoplasm but not in protein body I or II of rice seeds. Thus, our adaptation of the RNAi system improved the yield of a vaccine antigen with a high molecular weight. When the mucosal immunogenicity of the purified MucoRice-BoHc was examined, the vaccine induced protective immunity against a challenge with...Continue Reading
References
Mar 1, 1990·Molecular & General Genetics : MGG·T MasumuraS Fujii
Jun 1, 1984·Japanese Journal of Medical Science & Biology·H KondoG Sakaguchi
Jan 1, 1982·Pharmacology & Therapeutics·G Sakaguchi
Nov 1, 1994·Plant Molecular Biology·J Kohno-MuraseJ Imamura
Aug 12, 1999·Plant Physiology·T KatsubeF Takaiwa
Mar 21, 2001·Vaccine·S J StreatfieldJ A Howard
Oct 29, 2002·The Journal of Infectious Diseases·Mi-Na KweonHiroshi Kiyono
Oct 1, 1982·Plant Physiology·H YamagataZ Kasai
Feb 7, 2007·Expert Review of Vaccines·Kohtaro FujihashiDavid W Pascual
Jun 19, 2007·Proceedings of the National Academy of Sciences of the United States of America·Tomonori NochiHiroshi Kiyono
Aug 12, 2009·Vaccine·Yoshikazu YukiHiroshi Kiyono
Apr 28, 2010·Proceedings of the National Academy of Sciences of the United States of America·Daisuke TokuharaHiroshi Kiyono
Jul 14, 2010·Bioscience, Biotechnology, and Biochemistry·Yuhi SaitoTakehiro Masumura
Aug 3, 2010·Expert Review of Vaccines·Matthew Paul, Julian K-C Ma
Nov 13, 2010·Bioscience, Biotechnology, and Biochemistry·Masaharu KurodaChikako Mikami
Citations
Mar 1, 2013·Immunotherapy·Fumio Takaiwa
Jan 10, 2014·Planta·Satyajit SaurabhDinesh Prasad
May 11, 2013·Expert Review of Vaccines·Robert P Webb, Leonard A Smith
Feb 7, 2016·Regulatory Toxicology and Pharmacology : RTP·Yoshikazu YukiHiroshi Kiyono
Jun 24, 2015·Plant Biotechnology Journal·Fumio TakaiwaTakachika Hiroi
Sep 22, 2015·Plant Biotechnology Journal·Stephen J StreatfieldVidadi Yusibov
Oct 5, 2013·Biotechnology Journal·Yuhya Wakasa, Fumio Takaiwa
Apr 23, 2013·Plant Biotechnology Journal·Yoshikazu YukiHiroshi Kiyono
Sep 2, 2014·Bioscience, Biotechnology, and Biochemistry·Masaharu Kuroda, Sachiko Ikenaga
Feb 20, 2014·Journal of Biotechnology·Michiyo AbeHiroshi Kiyono
Apr 9, 2013·Bioengineered·Fumio Takaiwa
Dec 3, 2014·Vaccine·Aayam LamichhaneHiroshi Kiyonoa
Jul 17, 2014·Archivum Immunologiae Et Therapiae Experimentalis·Tatsuhiko AzegamiYoshikazu Yuki
Aug 5, 2014·Expert Review of Anti-infective Therapy·Fabrizio AnniballiCarlo Alessandro Locatelli
Dec 17, 2015·Therapeutic Advances in Vaccines·Natsumi TakeyamaYoshikazu Yuki
Aug 9, 2013·The Journal of Clinical Investigation·Daisuke TokuharaYoshikazu Yuki
Apr 3, 2016·British Journal of Clinical Pharmacology·Matilde MerlinLinda Avesani
Oct 28, 2017·Plant Cell Reports·Fumio TakaiwaKenjiro Ozawa
Mar 2, 2021·Transgenic Research·J F BuyelL Bortesi
Jun 15, 2013·Journal of Proteome Research·Shiho KurokawaYoshikazu Yuki